Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans : A prospective cohort study
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
AIM: Mitochondrial dysfunction is associated with the development of type 2 diabetes mellitus (T2DM). It is thus of clinical relevance to identify plasma biomarkers of mitochondrial dysfunction associated with the risk of T2DM. ATPase inhibitory factor 1 (IF1) endogenously inhibits mitochondrial ATP synthase activity. Here, we analyzed association of the plasma IF1 level with markers of glucose homeostasis and with the conversion to new-onset diabetes (NOD) in individuals with prediabetes.
METHODS: In the IT-DIAB prospective study, the baseline plasma level of IF1 was measured in 307 participants with prediabetes. The primary outcome was the incidence of NOD within five years of follow-up. Cross-sectional analysis of the IF1 level was also done in two independent interventional studies. Correlations between plasma IF1 and metabolic parameters at baseline were assessed by Spearman's correlation coefficients, and the association with the risk of NOD was determined using Cox proportional-hazards models.
RESULTS: In IT-DIAB, the mean IF1 plasma level was lower in participants who developed NOD than in those who did not (537 ± 248 versus 621 ± 313 ng/mL, P = 0.01). The plasma IF1 level negatively correlated with clinical variables associated with obesity and insulin resistance, including the body mass index (r = -0.20, P = 0.0005) and homeostasis model assessment of insulin resistance (HOMA-IR). (r = -0.37, P < 0.0001). Conversely, IF1 was positively associated with plasma markers of cardiometabolic health, such as HDL-C (r = 0.63, P < 0.0001) and apoA-I (r = 0.33, P < 0.0001). These correlations were confirmed in cross-sectional analyses. In IT-DIAB, the IF1 level was significantly associated with a lower risk of T2DM after adjustment for age, sex, and fasting plasma glucose (HR [95% CI] per 1 SD = 0.76 [0.62; 0.94], P = 0.012).
CONCLUSION: We identified for the first time the mitochondrial-related biomarker IF1 as being associated with the risk of T2DM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Diabetes & metabolism - 49(2023), 1 vom: 05. Jan., Seite 101391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pires Da Silva, Julie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ATP synthase |
|---|
| Anmerkungen: |
Date Completed 27.01.2023 Date Revised 22.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diabet.2022.101391 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346903920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346903920 | ||
| 003 | DE-627 | ||
| 005 | 20231226032548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2022.101391 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346903920 | ||
| 035 | |a (NLM)36174852 | ||
| 035 | |a (PII)S1262-3636(22)00073-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pires Da Silva, Julie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans |b A prospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2023 | ||
| 500 | |a Date Revised 22.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a AIM: Mitochondrial dysfunction is associated with the development of type 2 diabetes mellitus (T2DM). It is thus of clinical relevance to identify plasma biomarkers of mitochondrial dysfunction associated with the risk of T2DM. ATPase inhibitory factor 1 (IF1) endogenously inhibits mitochondrial ATP synthase activity. Here, we analyzed association of the plasma IF1 level with markers of glucose homeostasis and with the conversion to new-onset diabetes (NOD) in individuals with prediabetes | ||
| 520 | |a METHODS: In the IT-DIAB prospective study, the baseline plasma level of IF1 was measured in 307 participants with prediabetes. The primary outcome was the incidence of NOD within five years of follow-up. Cross-sectional analysis of the IF1 level was also done in two independent interventional studies. Correlations between plasma IF1 and metabolic parameters at baseline were assessed by Spearman's correlation coefficients, and the association with the risk of NOD was determined using Cox proportional-hazards models | ||
| 520 | |a RESULTS: In IT-DIAB, the mean IF1 plasma level was lower in participants who developed NOD than in those who did not (537 ± 248 versus 621 ± 313 ng/mL, P = 0.01). The plasma IF1 level negatively correlated with clinical variables associated with obesity and insulin resistance, including the body mass index (r = -0.20, P = 0.0005) and homeostasis model assessment of insulin resistance (HOMA-IR). (r = -0.37, P < 0.0001). Conversely, IF1 was positively associated with plasma markers of cardiometabolic health, such as HDL-C (r = 0.63, P < 0.0001) and apoA-I (r = 0.33, P < 0.0001). These correlations were confirmed in cross-sectional analyses. In IT-DIAB, the IF1 level was significantly associated with a lower risk of T2DM after adjustment for age, sex, and fasting plasma glucose (HR [95% CI] per 1 SD = 0.76 [0.62; 0.94], P = 0.012) | ||
| 520 | |a CONCLUSION: We identified for the first time the mitochondrial-related biomarker IF1 as being associated with the risk of T2DM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ATP synthase | |
| 650 | 4 | |a High-density lipoprotein | |
| 650 | 4 | |a IF1 | |
| 650 | 4 | |a Mitochondria | |
| 650 | 4 | |a New-onset diabetes | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Adenosine Triphosphatases |2 NLM | |
| 650 | 7 | |a EC 3.6.1.- |2 NLM | |
| 700 | 1 | |a Wargny, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Raffin, Jérémy |e verfasserin |4 aut | |
| 700 | 1 | |a Croyal, Mikaël |e verfasserin |4 aut | |
| 700 | 1 | |a Duparc, Thibaut |e verfasserin |4 aut | |
| 700 | 1 | |a Combes, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Genoux, Annelise |e verfasserin |4 aut | |
| 700 | 1 | |a Perret, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Vellas, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Guyonnet, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Thalamas, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Langin, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Moro, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Viguerie, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Rolland, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Barreto, Philipe de Souto |e verfasserin |4 aut | |
| 700 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Laurent O |e verfasserin |4 aut | |
| 700 | 0 | |a MAPT/DSA Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolism |d 1998 |g 49(2023), 1 vom: 05. Jan., Seite 101391 |w (DE-627)NLM086696130 |x 1878-1780 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:1 |g day:05 |g month:01 |g pages:101391 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabet.2022.101391 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 1 |b 05 |c 01 |h 101391 | ||